China approves Simcare’s cetuximab beta Enlituo

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

China approves Simcare’s cetuximab beta Enlituo

Biosimilars/News | Posted 30/07/2024 0 Post your comment

On 25 June 2024, Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group based in Nanjing, China, announced that Enlituo, a cetuximab beta injection, had received marketing approval from the China National Medical Administration (NMPA). This new-generation anti-epidermal growth factor receptor (EGFR) antibody drug was developed in collaboration with Mabpharm Limited.

Enlituo is a copy biological referencing Merck/Eli Lilly’s Erbitux. This cetuximab beta is classified as a 2.4 class modified biological new drug.

Cetuximab is a chimeric (mouse/human) monoclonal antibody. It inhibits EGFR epidermal growth factor receptor (EGFR) and is used to treat metastatic colorectal cancer, metastatic non-small cell lung cancer, and head and neck cancer [1].

In China, Enlituo is indicated for use in combination with the Folfiri regimen as a first-line treatment for RAS/BRAF wild-type metastatic colorectal cancer (mCRC). Mabpharm has obtained exclusive commercial rights of Enlituo in mainland China.

Enlituo received approval based on robust evidence from a phase II/III study and a phase III confirmatory clinical trial. In an open-label, randomized, controlled, multicentre, prospective phase III study, 505 subjects with RAS/BRAF wild-type mCRC were treated and analyzed. Clinical data revealed that combining cetuximab beta with Folfiri significantly extended progression-free survival (PFS) compared to Folfiri alone (13.133 months vs 9.567 months, p = 0.004). Additionally, the combination increased the objective response rate (ORR) (69.1% vs 42.3%, p < 0.001) and overall survival (OS) (2.322 years vs 1.900 years, p = 0.024).

According to the 'Cancer Incidence and Mortality in China, 2022' report by the National Cancer Center, colorectal cancer is the second most common cancer in China. Annually, there are 1,571 million new cases and 240,000 deaths. As such, the approval of Enlituo is significant for patients and for reducing the societal disease burden of colorectal cancer.

Back in 2017, biotech giant Amgen and Simcere entered into an exclusive agreement to co-develop and commercialize four copy biologicals in the areas of inflammation and oncology in China [2].

Positive phase III results for cetuximab and infliximab copy biologicals

LATIN AMERICAN FORUM
The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: Actualización de la guía de biosimilares intercambiables de la FDA sobre el enfoque revisado para los estudios de cambio

Browse the news in the Latin American Forum!

FORO LATINOAMERICANO
Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: Actualización de la guía de biosimilares intercambiables de la FDA sobre el enfoque revisado para los estudios de cambio

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.

References
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of cetuximab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Jul 30]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-cetuximab
2. GaBI Online - Generics and Biosimilars Initiative. Amgen and Simcere to collaborate on copy biologicals in China [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Jul 30]. Available from: www.gabionline.net/pharma-news/Amgen-and-Simcere-to-collaborate-on-copy-biologicals-in-China

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.